Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Valeant Pharmaceuticals International Inc. (T.BHC) had Stock-Based Compensation of 301.90M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-148.59M |
|
-- |
|
-- |
|
-- |
|
670.75M |
|
-- |
|
86.47M |
|
86.47M |
|
-135.18M |
|
-135.18M |
|
-135.18M |
|
-135.18M |
|
670.75M |
|
1.13B |
|
370.90M |
|
375.00M |
|
-0.39 |
|
-0.39 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
36.85B |
|
-- |
|
-- |
|
-- |
|
36.32B |
|
526.93M |
|
-21.72B |
|
526.93M |
|
370.53M |
|
| Cash Flow Statement Financials | |
1.96B |
|
-831.63M |
|
-1.04B |
|
1.68B |
|
1.85B |
|
173.31M |
|
|
Stock-Based Compensation |
301.90M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.47 |
|
-- |
|
-- |
|
0.98 |
|
55.31 |
|
71.51% |
|
17.15% |
|
17.15% |
|
-- |
|
2.21% |
|
-3.80% |
|
1.40B |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.49 |
|
1.19 |
|
75.61 |
|
-25.65% |
|
0.62% |
|
-0.37% |
|
-0.46% |
|
1.42 |
|
3.74 |
|
5.22 |
|